dapagliflozin + rosuvastatin

Dapagliflozin + rosuvastatin is a combination of two small molecule pharmaceuticals, each with distinct mechanisms and primary indications. Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used primarily to improve glycemic control in type 2 diabetes mellitus and to reduce cardiovascular and renal risk. Rosuvastatin is an HMG-CoA reductase inhibitor (statin) used to lower lipid levels and reduce the risk of cardiovascular disease, including myocardial infarction and stroke. Preclinical studies suggest that co-treatment with dapagliflozin and rosuvastatin may have synergistic cardioprotective effects, potentially through activation of the PI3K/Akt/mTOR signaling pathway[1][6]. However, there are also case reports suggesting an increased risk of rhabdomyolysis when these agents are combined[4]. There is no evidence that this specific combination has been developed or approved as a fixed-dose product; it refers to concurrent use rather than a single pharmaceutical formulation.

Brand names

Crestor + Farxiga

Other names

RSV + DGZ